Our founder, George Schlich, has a degree in Natural Sciences from
Cambridge University, UK, specialising in biology of cells, chemistry,
pathology, physiology, mathematics, pharmacology, and history and
philosophy of science. Highly regarded in the profession, George is
credited with "leading a great team" in this year's IAM1000.
George started his career with a mixture of small molecule chemistry from
US pharmaceutical companies and, closer to home, stem cell inventions from
the University of Edinburgh, UK and missile guidance systems from the
defence industry. This early experience has been expanded and built on over
the years. Since then, George has advised start-up companies as well as
small to medium to major corporate clients in Europe and the US across the
gamut of their IP interests, supporting flotations on London's AIM market.
Today, George has developed considerable experience in the protection of
inventions, via patents, designs, and trade marks, in areas from stem cells
to breakfast cereals, from recombinant proteins to vaccines and from
inhalation pharmaceuticals to cathode arc deposition of thin films. He
specialises in patents in the chemical and biochemical fields and also
advises on trade marks and designs. In relation to CRISPR/Cas9, George
represents Intellia Therapeutics, Inc.
George specialises in representing patent owners and opponents at
inter-partes hearings before the European Patent Office (EPO), the UK
Patent Office, and has extensive experience of Opposition and Appeals,
meriting an entry in the UK's "Legal 500".
CPA, EPA - SENIOR ASSOCIATE
CPA, EPA - ATTORNEY
CPA, EPA, RTMA ATTORNEY
CPA, EPA, RTMA - ATTORNEY
FIPAA - ATTORNEY